Table 4: TST positive versus TST negative patients. Univariate analyses.

Clinical and laboratory findingsTST positive ( )TST negative ( ) value

Age, years, mean ± SD 0.25
Patients with risk factors for LTBI, (%)2 (33)7 (8)0.10
SLE duration, median (IQR)90 (21–237)144 (60–225)0.72
SLEDAI, mean ± SD 0.64
SLICC, median (IQR)0 (0-1)0 (0-1)0.78
dsDNAn, UI/mL, median (IQR) 29 (2.45–61.25)13.50 (4.77–42.75)0.71
Prednisone > 7.5 mg/d, (%)0 (0)18 (32)0.68
Immunosuppressed patients, (%)1 (17)58 (98.3)0.021
Hydroxychloroquine treatment, (%)4 (66)75 (87)0.19
Steroid dose, mg, mean ± SD 0.11
Steroid cumulative dose, mg, mean ± SD 0.001
Cumulative steroids/disease duration, mg/year, mean ± SD 0.021
Mycophenolate dose, mg, mean ± SD0 0.001
Mycophenolate cumulative dose, mg, mean ± SD0 0.001
Cumulative mycophenolate/disease duration, mg/year, mean ± SD0 0.001
Methotrexate dose, mg, mean ± SD0 0.001
Methotrexate cumulative dose, mg, mean ± SD0 0.001
Cumulative methotrexate/disease duration, mg/year, mean ± SD0 0.001